Scientists are engineering bacteria to target and destroy cancer tumors while sparing healthy tissue, marking a shift toward living therapeutics that work differently from traditional chemotherapy and radiation.
Researchers modify bacteria strains to produce toxins or trigger immune responses specifically against cancer cells. The bacteria accumulate naturally in tumors because cancer tissue creates a low-oxygen environment that favors bacterial growth. Once concentrated in the tumor, engineered bacteria release cancer-killing compounds directly at the disease site, reducing systemic side effects that plague conventional treatments.
This approach builds on decades of cancer research. Clostridium and Salmonella species show particular promise because they thrive in anaerobic tumor conditions. Scientists add genetic circuits that activate tumor-killing mechanisms only in the presence of cancer markers, creating a "kill switch" to prevent harm to healthy cells.
The strategy addresses a core problem in cancer treatment. Traditional chemotherapy circulates throughout the body, damaging both malignant and normal cells. Bacterial therapeutics concentrate their action where it matters most, potentially lowering toxicity rates and improving patient outcomes.
Clinical applications remain early stage. Labs have demonstrated proof of concept in animal models, but human trials are limited. Regulatory bodies including the FDA are developing frameworks to evaluate living therapeutics, a category distinct from conventional drugs or gene therapies.
Questions persist about bacterial persistence, immune clearance, and off-target effects. Researchers must ensure engineered strains remain stable, do not evolve resistance, and can be controlled or eliminated if needed.
The work spans multiple institutions and represents convergence of synthetic biology, oncology, and microbiology. Success would expand treatment options for patients with solid tumors where bacteria naturally accumulate, offering an alternative pathway when surgery, radiation, or checkpoint inhibitors fall short.